COMMUNIQUÉS West-GlobeNewswire

-
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study
13/08/2025 -
Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results
13/08/2025 -
Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results
13/08/2025 -
First LockeT Cases Completed in Germany
13/08/2025 -
Clene to Present at the Emerging Growth Conference
13/08/2025 -
Cue Biopharma Announces Initiation of Investigator Sponsored Trial of CUE-102 in Recurrent Glioblastoma Multiforme
13/08/2025 -
Indaptus Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
13/08/2025 -
New Myriad Genetics Survey Uncovers Women Fear Screenings—But Feel Reassured by the Results
13/08/2025 -
Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership
13/08/2025 -
Mainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
13/08/2025 -
SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.
13/08/2025 -
Moleculin Reports Second Quarter 2025 Financial Results and Highlights
13/08/2025 -
Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection
13/08/2025 -
Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor
13/08/2025 -
MediWound Announces New EscharEx® Phase II Data Demonstrating Strong Link Between Wound Bed Preparation and Wound Closure in Venous Leg Ulcers
13/08/2025 -
24/7 Market News: LIXTE Biotechnology Holdings Embraces Cryptocurrency in Corporate Treasury Strategy
13/08/2025 -
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
13/08/2025 -
Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
13/08/2025 -
Dogwood Therapeutics Reports Second Quarter 2025 Financial Results
13/08/2025
Pages